BIOMAT Database Logo BIOMAT Database Logo

[Cross resistance in tumor cells and staphylococci with respect to anthracycline-group antineoplastic antibiotics]. 1976

V A Shorin, and L A Averbukh

The variants of the tumor cells of Fisher lymphadenosis, strain L-5178 and Staph. aureus resistant to rubomycin simultaneously became partially less sensitive to adriamycin. Sensitivity to karminomycin in the rubomycin resistant strains did not practically change as compared to the sensitivity of the initial strains. Sensitivity to adriamycin and rubomycin in Staph. aureus decreased 67 and 4 times respectively after 7 passages on media with increasing concentrations of adriamycin, while sensitivity to karminomycin decreased only 1.5 times, i.e. remained practically unchanged. After 22 passages of Staph. aureus to karminomycinrubomycin and adriamycin decreased 16, 67 and 33 times respectively. The results of the study may be explained by differences in the changes of the cell membrane permeability due to the drug effect.

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002360 Carubicin A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata. Carminomycin,Karminomycin,Carminomicin,Carminomycin I,Carminomycin II,Carminomycin III,Carubicin Hydrochloride,Demethyldaunomycin,Demethyldaunorubicin,Karminomicin,NSC-180,024,NSC-180024,Rubeomycin A,Rubeomycin A1,Hydrochloride, Carubicin,NSC 180,024,NSC 180024,NSC180,024,NSC180024
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug

Related Publications

V A Shorin, and L A Averbukh
[Effect of the anthracycline group antibiotics, mitomycin C and bruneomycin, on the transduction of drug resistance in staphylococci].
October 1978, Antibiotiki,
V A Shorin, and L A Averbukh
[Late effects of the hematotoxic action of antineoplastic antibiotics of the anthracycline group].
September 1988, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
V A Shorin, and L A Averbukh
[New antineoplastic antibiotics of the anthracycline group and the prospects of their clinical use].
May 1988, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
V A Shorin, and L A Averbukh
Resistance of staphylococci to antibiotics.
January 1956, Lectures on the scientific basis of medicine,
V A Shorin, and L A Averbukh
Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics.
March 1979, Journal of pharmaceutical sciences,
V A Shorin, and L A Averbukh
Resistance of micrococci (staphylococci) to antibiotics.
April 1955, Annals of internal medicine,
V A Shorin, and L A Averbukh
[Resistance of staphylococci to antibiotics in pyoderma].
January 1958, Vestnik dermatologii i venerologii,
V A Shorin, and L A Averbukh
Biochemical mechanism for resistance to anthracycline antibiotics.
January 1986, Progress in clinical and biological research,
V A Shorin, and L A Averbukh
A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.
December 1996, Drug safety,
V A Shorin, and L A Averbukh
Hospital cross-infections with staphylococci resistant to several antibiotics.
June 1952, Lancet (London, England),
Copied contents to your clipboard!